Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PRKCA | P17252 | 4/20 | 0.34 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.34 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.34 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.34 |
| ▸ | LPAR3 | Q9UBY5 | 6/20 | 0.33 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1030922 | 0.85 | SERPINE1 (0.36) | ALDH1A1LMNAPRKCA | |
| SCHEMBL5483539 | 0.83 | CTSK (0.32) | ALDH1A1LMNATSHR | |
| SCHEMBL20955971 | 0.83 | ALDH1A1 (0.38) | ALDH1A1LMNATSHR | |
| SCHEMBL8928153 | 0.83 | ALDH1A1 (0.45) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL7534968 | 0.82 | PRKCA (0.36) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL162345 | 0.81 | ALDH1A1 (0.36) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL7206885 | 0.79 | PRKCA (0.37) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL1275748 | 0.78 | ALDH1A1 (0.43) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL7054088 | 0.78 | ALDH1A1 (0.36) | ALDH1A1TSHR | |
| SCHEMBL4349644 | 0.78 | ALDH1A1 (0.33) | ALDH1A1LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11197818-B2 | Aqueous emulsions of carbamato-functionalized organopolysiloxanes | WACKER CHEMIE AG (DE) | 2021-12-14 | — | — | US | disclosed |
| CN-109152723-B | Aqueous emulsions of carbamate-functional organopolysiloxanes | 瓦克化学股份公司 | 2021-11-09 | — | — | CN | disclosed |
| CN-108779415-B | Composition containing carbamate-functional organopolysiloxane and cationic surfactant | 瓦克化学股份公司 | 2021-11-05 | — | — | CN | disclosed |
| US-10675230-B2 | Compositions comprising carbamate functionalized organopolysiloxanes and cationic surfactants | WACKER CHEMIE AG (DE) | 2020-06-09 | — | — | US | disclosed |
| US-20190133906-A1 | COMPOSITIONS COMPRISING CARBAMATE FUNCTIONALIZED ORGANOPOLYSILOXANES AND CATIONIC SURFACTANTS | WACKER CHEMIE AG (DE) | 2019-05-09 | — | — | US | disclosed |
| US-20190133919-A1 | AQUEOUS EMULSIONS OF CARBAMATO-FUNCTIONALIZED ORGANOPOLYSILOXANES | WACKER CHEMIE AG (DE) | 2019-05-09 | — | — | US | disclosed |
| EP-0893428-B1 | A process for preparing dialkyl carbonates | NIPPON CATALYTIC CHEM IND (JP) | 2003-01-22 | — | — | EP | disclosed |
| EP-0599287-B1 | A process for preparing dialkyl carbonates | NIPPON CATALYTIC CHEM IND (JP) | 1999-04-07 | — | — | EP | disclosed |
| EP-0893428-A1 | A process for preparing dialkyl carbonates | NIPPON SHOKUBAI CO., LTD. (JP) | 1999-01-27 | — | — | EP | disclosed |
| US-5430170-A | Esterification of alkalene carbonate with an alcohol in presence of rare earth catalyst | NIPPON SHOKUBAI CO., LTD. (JP) | 1995-07-04 | — | — | US | disclosed |
| EP-0599287-A1 | A process for preparing dialkyl carbonates | NIPPON SHOKUBAI CO., LTD. (JP) | 1994-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10675230-B2 | Compositions comprising carbamate functionalized organopolysiloxanes and cationic surfactants | C9, CUTA, NISCH | ALDH1A1 3674/4885LMNA 1927/4885PRKCA 4315/4885 |
| US-11197818-B2 | Aqueous emulsions of carbamato-functionalized organopolysiloxanes | HMBS, CBLB, LIPA | ALDH1A1 2689/4885LMNA 1089/4885PRKCA 4324/4885 |
| US-20190133906-A1 | COMPOSITIONS COMPRISING CARBAMATE FUNCTIONALIZED ORGANOPOLYSILOXANES AND CATIONIC SURFACTANTS | C9, CUTA, NISCH | ALDH1A1 3674/4885LMNA 1927/4885PRKCA 4315/4885 |
| US-20190133919-A1 | AQUEOUS EMULSIONS OF CARBAMATO-FUNCTIONALIZED ORGANOPOLYSILOXANES | HMBS, CBLB, LIPA | ALDH1A1 2689/4885LMNA 1089/4885PRKCA 4324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.